{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:42:13Z","timestamp":1791049333885,"version":"4.1.0"},"reference-count":79,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1497,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1751-7176.2011.00518.x","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T17:53:55Z","timestamp":1311789235000},"page":"677-686","source":"Crossref","is-referenced-by-count":88,"title":["Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety"],"prefix":"10.1111","volume":"13","author":[{"given":"Addison A.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmy","family":"Siragy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,27]]},"reference":[{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2006.003","article-title":"Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research","volume":"7","author":"Ferrario","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.mcna.2009.02.015","article-title":"Oxidative stress and hypertension","volume":"93","author":"Harrison","year":"2009","journal-title":"Med Clin North Am"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/CS20060247","article-title":"Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions","volume":"112","author":"Savoia","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB4|cit4","first-page":"CD003822","article-title":"Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension","volume":"4","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-009-0081-y","article-title":"Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering","volume":"10","author":"Ismail","year":"2010","journal-title":"Curr Diab Rep"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1751-7176.2010.00379.x","article-title":"Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy","volume":"13","author":"Toth","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/HJH.0b013e3282f56ba5","article-title":"Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?","volume":"26","author":"Benson","year":"2008","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00004872-199917030-00019","article-title":"Effect of losartan on human platelet activation","volume":"17","author":"Guerra-Cuesta","year":"1999","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00005344-200104000-00007","article-title":"Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan","volume":"37","author":"Jimenez","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5551\/jat.14.31","article-title":"Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers","volume":"14","author":"Sato","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.07.003","article-title":"Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke","volume":"16","author":"Yamada","year":"2007","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1524-6175.2005.05264.x","article-title":"The pleiotropic effects of angiotensin receptor blockers","volume":"8","author":"Chrysant","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.jhh.1001916","article-title":"Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence","volume":"19","author":"Chrysant","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1111\/j.1751-7176.2011.00518.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/S0895-7061(99)00250-2","article-title":"Newly emerging pharmacologic differences in angiotensin II receptor blockers","volume":"13(","author":"Oparil","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB22|cit22","first-page":"611","article-title":"Olmesartan medoxomil for hypertension: a clinical review, Drug forecast","volume":"27","author":"Norwood","year":"2002","journal-title":"P & T"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HCO.0b013e32832c58ba","article-title":"Has pharmacogenetics brought us closer to \u2018personalized medicine\u2019 for initial drug treatment of hypertension?","volume":"24","author":"Arnett","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ajh.2008.190","article-title":"The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial","volume":"21","author":"Kurland","year":"2008","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1111\/j.1751-7176.2011.00518.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FPC.0b013e328333f70b","article-title":"Effect of ACE insertion\/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study","volume":"20","author":"Nordestgaard","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1111\/j.1751-7176.2011.00518.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1517\/14656560903512962","article-title":"Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan","volume":"11","author":"Bramlage","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB27|cit27","first-page":"22","article-title":"Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions","volume":"36","author":"Munger","year":"2011","journal-title":"P & T"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0009-9236(98)90163-1","article-title":"Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers","volume":"63","author":"Williamson","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002280050405","article-title":"Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174","volume":"53","author":"Kaukonen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1081-1206(10)60288-8","article-title":"Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis","volume":"101","author":"Haymore","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1524-6175.2002.01509.x","article-title":"Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1524-6175.2005.04666.x","article-title":"Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients","volume":"7","author":"Bakris","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB34|cit34","first-page":"CD003823","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","volume":"4","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB35|cit35","doi-asserted-by":"crossref","unstructured":"Matchar DB McCrory DC Orlando LA et\u00a0al. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension 2007","DOI":"10.7326\/0003-4819-148-1-200801010-00189"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","article-title":"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension","volume":"3","author":"Oparil","year":"2001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","article-title":"Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension","volume":"9","author":"Giles","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfn230","article-title":"Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy","volume":"23","author":"Galle","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":"The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure","volume":"13","author":"Bakris","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1527-5299.2003.03269.x","article-title":"Adherence to antihypertensive therapy with fixed-dose amlodipine besylate\/benazepril HCl versus comparable component-based therapy","volume":"9","author":"Taylor","year":"2003","journal-title":"Congest Heart Fail"},{"issue":"Suppl 1","key":"10.1111\/j.1751-7176.2011.00518.x-BIB42|cit42","first-page":"162","article-title":"Efficacy and safety of azilsartan medoximil\/chlorthalidone vs olmesartan\/HCTZ combinations in stage 2 systolic hypertension","volume":"13","author":"Cushman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jama.202.11.1028","article-title":"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129\u2003mm Hg","volume":"202","author":"VA Cooperative Study Group","year":"1967","journal-title":"JAMA"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","article-title":"Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial","volume":"54","author":"Calhoun","year":"2009","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","article-title":"Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study","volume":"32","author":"Oparil","year":"2010","journal-title":"Clin Ther"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB47|cit47","doi-asserted-by":"crossref","DOI":"10.1038\/jhh.2010.115","article-title":"24-hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension","author":"Lacourciere","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1751-7176.2009.00114.x","article-title":"Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone","volume":"11","author":"Geiger","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1185\/03007995.2010.528282","article-title":"Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension","volume":"26","author":"Chrysant","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00004872-199816090-00014","article-title":"Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension","volume":"16","author":"Bigazzi","year":"1998","journal-title":"J Hypertens"},{"issue":"Suppl 4","key":"10.1111\/j.1751-7176.2011.00518.x-BIB51|cit51","first-page":"64","article-title":"Microalbuminuria, endothelial dysfunction and cardiovascular risk","volume":"26","author":"Feldt-Rasmussen","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study","volume":"139","author":"Wachtell","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11886-009-0063-3","article-title":"The current state of RAAS blockade in the treatment of hypertension and proteinuria","volume":"11","author":"Kalaitzidis","year":"2009","journal-title":"Curr Cardiol Rep"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajh.2008.16","article-title":"Left ventricular hypertrophy and clinical outcomes in hypertensive patients","volume":"21","author":"Ruilope","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/HYPERTENSIONAHA.106.085654","article-title":"Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population","volume":"50","author":"Aksnes","year":"2007","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.108.111674","article-title":"Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering","volume":"51","author":"Karalliedde","year":"2008","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1291\/hypres.26.609","article-title":"Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients","volume":"26","author":"Takami","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.109.131466","article-title":"Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients","volume":"54","author":"Matsui","year":"2009","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00228-005-0931-8","article-title":"Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension","volume":"61","author":"Anan","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1089\/ars.2007.1986","article-title":"Redox signaling, vascular function, and hypertension","volume":"10","author":"Lee","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB69|cit69","first-page":"233","article-title":"The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man","volume":"5","author":"Del","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(08)70040-1","article-title":"Vascular cognitive impairment: current concepts and clinical developments","volume":"7","author":"Moorhouse","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/08037050802169644","article-title":"Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial","volume":"17","author":"Kjeldsen","year":"2008","journal-title":"Blood Press"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","article-title":"Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial","volume":"26","author":"Schmieder","year":"2008","journal-title":"J Hypertens"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.CIR.0000083724.28630.C3","article-title":"Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study","volume":"108","author":"Okin","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.HYP.0000151324.05355.1c","article-title":"Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study","volume":"45","author":"Kizer","year":"2005","journal-title":"Hypertension"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1751-7176.2011.00518.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1751-7176.2011.00518.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T07:20:34Z","timestamp":1625556034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1751-7176.2011.00518.x"}},"subtitle":["Angiotensin Receptor Blockers"],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00518.x","relation":{},"ISSN":["1524-6175"],"issn-type":[{"value":"1524-6175","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}